Highlights United Therapeutics Corporation

Equities

UTHR

US91307C1027

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2025-07-11 EDT			5-day change	1st Jan Change
295.52 ^USD	-1.55%		+0.35%	-16.25%

06-30	United Therapeutics' Tyvaso to Benefit from Q2 Seasonality, UBS Says	MT
06-30	UBS Adjusts Price Target on United Therapeutics to $385 From $410, Maintains Buy Rating	MT

Highlights

United Therapeutics Corporation and Intermountain Health Announce the First Patient Treated with External Liver Support Using a Bioengineered Liver	06-24	CI
United Therapeutics Corporation Concludes Enrollment of the Advance Outcomes Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension	06-23	CI
Insmed's drug for rare lung disease achieves 'home run' in mid-stage trial	06-10	RE
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension	06-02	MT
Liquidia Receives FDA Approval on Yutrepia for Treatment of Pulmonary Hypertension	05-23	MT
Liquidia Faces Patent Litigation Filed by United Therapeutics	05-12	MT
Liquidia Says New Litigation Filed Against Co In U.S.	05-12	RE
United Therapeutics Q1 Earnings, Revenue Rise	04-30	MT
Earnings Flash (UTHR) United Therapeutics Posts Q1 Revenue $794.4M, vs. FactSet Est of $729.3M	04-30	MT
United Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	04-30	CI
Correction: United Therapeutics Q4 Net Income, Revenue Rise	02-26	MT
United Therapeutics Q4 Net Income Increases, Revenue Drops	02-26	MT
Earnings Flash (UTHR) United Therapeutics Posts Q4 Revenue $735.9M, vs. FactSet Est of $734.7M	02-26	MT
United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	02-26	CI
United Therapeutics Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2024	02-26	CI
United Therapeutics Completes Patient Enrollment for Another Trial of Idiopathic Pulmonary Fibrosis Treatment	02-04	MT
United Therapeutics Fully Enrolls Teton 1 Study Of Inhaled Treprostinil For Idiopathic Pulmonary Fibrosis	02-04	RE
United Therapeutics Corporation Announces Full Enrollment of the Teton 1 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary Fibrosis	02-04	CI
BofA Adjusts Price Target on United Therapeutics to $328 From $327	02-03	MT
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial	02-03	CI
UBS Raises Price Target on United Therapeutics to $475 From $415, Keeps Buy Rating	01-08	MT
United Therapeutics Seeks M&A	24-10-30	CI
United Therapeutics' Q3 Earnings, Revenue Rise	24-10-30	MT
Earnings Flash (UTHR) UNITED THERAPEUTICS CORPORATION Posts Q3 Revenue $748.9M	24-10-30	MT
Tranche Update on United Therapeutics Corporation's Equity Buyback Plan announced on March 25, 2024.	24-10-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

United Therapeutics delivers 18th consecutive quarter of topline growth

June 17, 2025 at 06:16 am